Abstract
In this expanded access program providing ruxolitinib for the emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization, ruxolitinib 5 mg twice daily (preferred regimen when tolerated) improved clinical status by ≥ 1 point in nearly half of the patients. Ruxolitinib was generally well tolerated, with no thrombotic serious adverse events reported. Randomized controlled trials are warranted to further assess clinical benefit and identify patients with severe COVID‐19 infection who respond to Janus kinase inhibition.